Media Inquiries: For all MAVA media inquiries, please contact us at 703-506-9300 or email


Check back regularly for news, coverage, and announcements about MAVA.


NEA Leads $27M Series A-1 in Mersana Therapeutics

Mersana Therapeutics, Inc., a biopharmaceutical company developing its Fleximer  antibody-drug  conjugate (ADC) platform and pipeline of small molecule Fleximer conjugates, announced that it has closed a $27 million Series A-1 financing led by new investor New Enterprise Associates (NEA).  Participation in the round also included new investor Pfizer Venture Investments and existing investors Fidelity Biosciences, ProQuest Investments, Rho Ventures and Harris and Harris Group.

Read More